Literature DB >> 21482799

Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.

Justin V Louis1, Ellen Martens, Peter Borghgraef, Caroline Lambrecht, Ward Sents, Sari Longin, Karen Zwaenepoel, Robert Pijnenborg, Isabelle Landrieu, Guy Lippens, Birgit Ledermann, Jürgen Götz, Fred Van Leuven, Jozef Goris, Veerle Janssens.   

Abstract

Functional diversity of protein phosphatase 2A (PP2A) enzymes mainly results from their association with distinct regulatory subunits. To analyze the functions of one such holoenzyme in vivo, we generated mice lacking PR61/B'δ (B56δ), a subunit highly expressed in neural tissues. In PR61/B'δ-null mice the microtubule-associated protein tau becomes progressively phosphorylated at pathological epitopes in restricted brain areas, with marked immunoreactivity for the misfolded MC1-conformation but without neurofibrillary tangle formation. Behavioral tests indicated impaired sensorimotor but normal cognitive functions. These phenotypical characteristics were further underscored in PR61/B'δ-null mice mildly overexpressing human tau. PR61/B'δ-containing PP2A (PP2A(T61δ)) poorly dephosphorylates tau in vitro, arguing against a direct dephosphorylation defect. Rather, the activity of glycogen synthase kinase-3β, a major tau kinase, was found increased, with decreased phosphorylation of Ser-9, a putative cyclin-dependent kinase 5 (CDK5) target. Accordingly, CDK5 activity is decreased, and its cellular activator p35, strikingly absent in the affected brain areas. As opposed to tau, p35 is an excellent PP2A(T61δ) substrate. Our data imply a nonredundant function for PR61/B'δ in phospho-tau homeostasis via an unexpected spatially restricted mechanism preventing p35 hyperphosphorylation and its subsequent degradation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482799      PMCID: PMC3084077          DOI: 10.1073/pnas.1018777108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.

Authors:  G A Jicha; R Bowser; I G Kazam; P Davies
Journal:  J Neurosci Res       Date:  1997-04-15       Impact factor: 4.164

Review 2.  PP2A: the expected tumor suppressor.

Authors:  Veerle Janssens; Jozef Goris; Christine Van Hoof
Journal:  Curr Opin Genet Dev       Date:  2005-02       Impact factor: 5.578

3.  Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Calpha.

Authors:  J Götz; A Probst; E Ehler; B Hemmings; W Kues
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

4.  Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits.

Authors:  S Strack; J A Zaucha; F F Ebner; R J Colbran; B E Wadzinski
Journal:  J Comp Neurol       Date:  1998-03-23       Impact factor: 3.215

Review 5.  Functions of B56-containing PP2As in major developmental and cancer signaling pathways.

Authors:  Jing Yang; Christopher Phiel
Journal:  Life Sci       Date:  2010-10-08       Impact factor: 5.037

Review 6.  Tau phosphorylation in neuronal cell function and dysfunction.

Authors:  Gail V W Johnson; William H Stoothoff
Journal:  J Cell Sci       Date:  2004-11-15       Impact factor: 5.285

7.  Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies.

Authors:  E Sontag; V Nunbhakdi-Craig; G Lee; R Brandt; C Kamibayashi; J Kuret; C L White; M C Mumby; G S Bloom
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

8.  p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.

Authors:  G N Patrick; P Zhou; Y T Kwon; P M Howley; L H Tsai
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

9.  Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death.

Authors:  T Ohshima; J M Ward; C G Huh; G Longenecker; H C Pant; R O Brady; L J Martin; A B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Okadaic acid-stimulated degradation of p35, an activator of CDK5, by proteasome in cultured neurons.

Authors:  T Saito; K Ishiguro; R Onuki; Y Nagai; T Kishimoto; S Hisanaga
Journal:  Biochem Biophys Res Commun       Date:  1998-11-27       Impact factor: 3.575

View more
  53 in total

1.  Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Alexander M Herman; G William Rebeck; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2011-09-14       Impact factor: 4.314

2.  Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease.

Authors:  Yash B Joshi; Jin Chu; Domenico Praticò
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

4.  Nuclear life of the voltage-gated Cacnb4 subunit and its role in gene transcription regulation.

Authors:  Michel Ronjat; Shigeki Kiyonaka; Maud Barbado; Michel De Waard; Yasuo Mori
Journal:  Channels (Austin)       Date:  2013-03-01       Impact factor: 2.581

Review 5.  Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.

Authors:  Parthasarathy Seshacharyulu; Poomy Pandey; Kaustubh Datta; Surinder K Batra
Journal:  Cancer Lett       Date:  2013-02-20       Impact factor: 8.679

Review 6.  PP2A as a master regulator of the cell cycle.

Authors:  Nathan Wlodarchak; Yongna Xing
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-02-24       Impact factor: 8.250

Review 7.  Protein phosphatases and Alzheimer's disease.

Authors:  Steven P Braithwaite; Jeffry B Stock; Paul J Lombroso; Angus C Nairn
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

8.  Reduced Expression of the PP2A Methylesterase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Sensitivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice.

Authors:  Agnieszka Staniszewski; Hong Zhang; Kesava Asam; Rose Pitstick; Michael P Kavanaugh; Ottavio Arancio; Russell E Nicholls
Journal:  J Neurosci       Date:  2020-04-27       Impact factor: 6.167

9.  De novo missense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism.

Authors:  Linshan Shang; Lindsay B Henderson; Megan T Cho; Donald S Petrey; Chin-To Fong; Katrina M Haude; Natasha Shur; Julie Lundberg; Natalie Hauser; Jason Carmichael; Jeffrey Innis; Jane Schuette; Yvonne W Wu; Shailesh Asaikar; Margaret Pearson; Leandra Folk; Kyle Retterer; Kristin G Monaghan; Wendy K Chung
Journal:  Neurogenetics       Date:  2015-11-17       Impact factor: 2.660

10.  Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers.

Authors:  Caroline Lambrecht; Gabriela Bomfim Ferreira; Judit DomÈnech Omella; Louis Libbrecht; Rita DE Vos; Rita Derua; Chantal Mathieu; Lut Overbergh; Etienne Waelkens; Veerle Janssens
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.